Frontotemporal Lobar Degeneration  >>  LMTX (hydromethylthionine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LMTX (hydromethylthionine) / TauRx
NCT01626378 / 2011-005529-34: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Checkmark
Sep 2016 - Sep 2016: 
Checkmark
Jul 2016 - Jul 2016: 
Completed
3
220
US, Canada, Europe, RoW
TRx0237, Placebo
TauRx Therapeutics Ltd
Behavioral Variant Frontotemporal Dementia (bvFTD)
02/16
02/16
NCT02245568 / 2014-002013-37: Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Checkmark
Aug 2014 - Aug 2014: 
Terminated
3
913
Europe, Canada, US, RoW
LMTM
TauRx Therapeutics Ltd
Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
05/17
05/17

Download Options